- Home
- DMAC vs WTI Comparison
DMAC vs WTI Comparison
Compare DMAC & WTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- WTI
- Stock Information
- Founded
- DMAC 2000
- WTI 1983
- Country
- DMAC United States
- WTI United States
- Employees
- DMAC N/A
- WTI N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- WTI Oil & Gas Production
- Sector
- DMAC Health Care
- WTI Energy
- Exchange
- DMAC Nasdaq
- WTI Nasdaq
- Market Cap
- DMAC 310.1M
- WTI 332.3M
- IPO Year
- DMAC N/A
- WTI 2005
- Fundamental
- Price
- DMAC $7.06
- WTI $2.10
- Analyst Decision
- DMAC Strong Buy
- WTI
- Analyst Count
- DMAC 3
- WTI 0
- Target Price
- DMAC $12.33
- WTI N/A
- AVG Volume (30 Days)
- DMAC 262.5K
- WTI 2.6M
- Earning Date
- DMAC 11-12-2025
- WTI 11-05-2025
- Dividend Yield
- DMAC N/A
- WTI 1.90%
- EPS Growth
- DMAC N/A
- WTI N/A
- EPS
- DMAC N/A
- WTI N/A
- Revenue
- DMAC N/A
- WTI $493,951,000.00
- Revenue This Year
- DMAC N/A
- WTI $7.18
- Revenue Next Year
- DMAC N/A
- WTI $5.71
- P/E Ratio
- DMAC N/A
- WTI N/A
- Revenue Growth
- DMAC N/A
- WTI N/A
- 52 Week Low
- DMAC $3.19
- WTI $1.09
- 52 Week High
- DMAC $7.49
- WTI $2.59
- Technical
- Relative Strength Index (RSI)
- DMAC 57.38
- WTI 50.56
- Support Level
- DMAC $6.64
- WTI $2.05
- Resistance Level
- DMAC $7.13
- WTI $2.20
- Average True Range (ATR)
- DMAC 0.27
- WTI 0.12
- MACD
- DMAC -0.00
- WTI -0.03
- Stochastic Oscillator
- DMAC 77.21
- WTI 20.93
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About WTI W&T Offshore Inc.
W&T Offshore Inc is an oil and gas exploration and production company. The company's exploration operations are focused in the Gulf of Mexico, where it drills for oil and gas. The company engages in both deepwater drilling and shallow-water shelf drilling. W&T Offshore extracts crude oil, natural gas, and natural gas liquids, which are then sold directly at the wellhead. Overall, crude oil accounts for the majority of company's revenue, with natural gas accounting for a much smaller portion.